HomeCompareAQSZF vs GBDC

AQSZF vs GBDC: Dividend Comparison 2026

AQSZF yields 51282.05% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AQSZF wins by $6.164318307325471e+23M in total portfolio value
10 years
AQSZF
AQSZF
● Live price
51282.05%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.164318307325471e+23M
Annual income
$614,076,267,853,163,140,000,000,000,000.00
Full AQSZF calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — AQSZF vs GBDC

📍 AQSZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAQSZFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AQSZF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AQSZF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AQSZF
Annual income on $10K today (after 15% tax)
$4,358,974.36/yr
After 10yr DRIP, annual income (after tax)
$521,964,827,675,188,650,000,000,000,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, AQSZF beats the other by $521,964,827,675,188,650,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AQSZF + GBDC for your $10,000?

AQSZF: 50%GBDC: 50%
100% GBDC50/50100% AQSZF
Portfolio after 10yr
$3.0821591536627355e+23M
Annual income
$307,038,133,926,581,570,000,000,000,000.00/yr
Blended yield
99.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

AQSZF
No analyst data
Altman Z
-297.9
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AQSZF buys
0
GBDC buys
0
No recent congressional trades found for AQSZF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAQSZFGBDC
Forward yield51282.05%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$6.164318307325471e+23M$20.78M
Annual income after 10y$614,076,267,853,163,140,000,000,000,000.00$16,389,263.41
Total dividends collected$6.16277212408334e+23M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: AQSZF vs GBDC ($10,000, DRIP)

YearAQSZF PortfolioAQSZF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$5,138,905$5,128,205.13$12,490$1,790.28+$5.13MAQSZF
2$2,468,429,435$2,462,930,806.71$16,522$3,157.73+$2468.41MAQSZF
3$1,108,293,458,836$1,105,652,239,339.88$23,578$5,898.68+$1108293.44MAQSZF
4$465,133,359,857,093$463,947,485,856,138.75$37,115$11,886.75+$465133359.82MAQSZF
5$182,471,032,796,869,920$181,973,340,101,822,850.00$66,136$26,423.57+$182471032796.80MAQSZF
6$66,912,846,333,441,070,000$66,717,602,328,348,430,000.00$137,257$66,491.44+$66912846333440.94MAQSZF
7$22,936,650,503,380,730,000,000$22,865,053,757,803,946,000,000.00$341,734$194,868.54+$22936650503380732.00MAQSZF
8$7,349,564,359,975,759,000,000,000$7,325,022,143,937,141,000,000,000.00$1,050,788$685,133.02+$7349564359975758848.00MAQSZF
9$2,201,460,634,938,307,300,000,000,000$2,193,596,601,073,133,400,000,000,000.00$4,099,314$2,974,971.01+$2.2014606349383072e+21MAQSZF
10$616,431,830,732,547,100,000,000,000,000$614,076,267,853,163,140,000,000,000,000.00$20,775,530$16,389,263.41+$6.164318307325471e+23MAQSZF

AQSZF vs GBDC: Complete Analysis 2026

AQSZFStock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Full AQSZF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this AQSZF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AQSZF vs SCHDAQSZF vs JEPIAQSZF vs OAQSZF vs KOAQSZF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.